Last updated: October 21, 2026
Brenzavvy is the U.S. brand for bexagliflozin, a once-daily oral SGLT2 inhibitor approved by the FDA on December 22, 2023, for adults with type 2 diabetes as an adjunct to diet and exercise. Its excipient system is conventional, low-cost, and compatible with standard immediate-release tablet manufacturing. The largest commercial opportunities are generic supply, fixed-dose combinations, pediatric or geriatric adaptations, and differentiated packaging rather than proprietary excipient technology.
What excipients are used in Brenzavvy tablets?
The FDA prescribing information identifies six inactive ingredients in Brenzavvy 20 mg tablets: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate (FDA, 2023a).
| Excipient |
Likely functional role |
Commercial significance |
| Microcrystalline cellulose |
Diluent, compressibility aid |
Widely available; supports direct compression |
| Croscarmellose sodium |
Superdisintegrant |
Helps rapid tablet breakup and dissolution |
| Povidone |
Binder |
Supports granulation and tablet mechanical strength |
| Sodium lauryl sulfate |
Wetting and surfactant agent |
Can improve powder wetting and dissolution |
| Colloidal silicon dioxide |
Glidant, flow aid |
Improves powder flow and content uniformity |
| Magnesium stearate |
Lubricant |
Reduces ejection force and tooling adhesion |
The formulation has no publicly identified novel excipient. It uses standard pharmaceutical-grade materials with established compendial supply chains. That structure reduces manufacturing barriers for an eventual generic or authorized-generic product.
How does the Brenzavvy formulation affect manufacturing costs?
Brenzavvy is supplied as a 20 mg oral tablet taken once daily, with or without food. The product does not require a specialized delivery device, sterile processing, cold-chain distribution, or complex release-control technology (FDA, 2023a).
The formulation supports a conventional manufacturing sequence:
- Dispensing and screening of active pharmaceutical ingredient and excipients.
- Blending with microcrystalline cellulose, croscarmellose sodium, povidone, and silicon dioxide.
- Lubrication with magnesium stearate.
- Compression into tablets.
- Film coating or surface finishing, if applicable to the commercial presentation.
- Packaging in moisture-protective containers.
The cost structure should be driven primarily by bexagliflozin API, quality-control testing, packaging, and scale rather than by excipient cost. Most listed excipients are inexpensive relative to API and can be sourced from multiple suppliers.
The main technical risks are standard solid-dose risks:
- Poor blend uniformity at low drug loading.
- Over-lubrication from magnesium stearate, which can reduce dissolution.
- Inadequate wetting if sodium lauryl sulfate concentration is poorly controlled.
- Tablet capping or lamination during scale-up.
- Dissolution changes caused by particle-size or density differences among excipient grades.
- Moisture-related variability in croscarmellose sodium and microcrystalline cellulose.
These risks are manageable through design-of-experiments work, excipient-grade qualification, blend uniformity testing, tablet hardness control, friability testing, and comparative dissolution.
What formulation patents protect Brenzavvy?
Public regulatory materials identify Brenzavvy as a bexagliflozin drug product but do not establish that the marketed excipient combination is protected by a separate, commercially decisive formulation patent. The strongest intellectual-property risk is more likely to arise from patents covering bexagliflozin composition of matter, crystalline forms, manufacturing processes, or therapeutic use.
The commercial formulation itself uses common excipients. A generic sponsor could likely design around individual formulation claims by changing:
- The binder system.
- The disintegrant.
- The surfactant.
- The tablet manufacturing process.
- The coating system.
- The excipient grade or concentration.
- The tablet strength or presentation.
A formulation patent would have greater practical value if it claimed a narrow dissolution profile, stability advantage, impurity-control method, or manufacturing process that could not be readily replicated with alternative excipient systems.
How strong is the excipient patent estate?
The excipient-related estate appears limited in strategic strength compared with a conventional composition-of-matter estate. Standard excipients create several design-around routes, and their functions are well established in the pharmaceutical literature and compendia.
Potentially stronger claims would involve:
- A defined bexagliflozin particle-size distribution.
- A specific polymorphic or crystalline form.
- A manufacturing process that controls degradation products.
- A narrow dissolution profile linked to clinical performance.
- A stability-enhancing formulation under high humidity or accelerated conditions.
- A fixed-dose combination with another diabetes agent.
These claim categories can raise development costs even when the basic tablet formulation is simple.
When does Brenzavvy lose exclusivity?
Brenzavvy received FDA approval on December 22, 2023, under NDA 214373, according to the FDA approval materials (FDA, 2023b). If bexagliflozin received standard new chemical entity exclusivity, the likely regulatory framework is:
| Milestone |
Date or period |
| FDA approval |
December 22, 2023 |
| Four-year ANDA submission block under NCE exclusivity |
Through December 22, 2027 |
| Five-year NCE approval protection |
Through December 22, 2028 |
| Earliest routine generic approval absent patent barriers |
December 22, 2028 |
| Possible earlier Paragraph IV activity |
From the fourth year, subject to applicable patent listings |
Patent expiry may extend market protection beyond the regulatory exclusivity period. Patent term adjustment, patent-term extension, pediatric exclusivity, listed method-of-use patents, and litigation settlements can change the effective generic-entry date.
The FDA Orange Book must be used to confirm listed patents, expiration dates, pediatric extensions, and any approved drug-product or method-of-use patents. A generic applicant would also assess unlisted process, crystalline-form, manufacturing, and contractual risks outside the Orange Book framework (FDA, 2024).
What is the Orange Book status of Brenzavvy?
Brenzavvy is an FDA-approved small-molecule drug and is evaluated through the abbreviated new drug application pathway for future generic competition. It is not a biologic and does not create a biosimilar pathway.
Relevant Orange Book issues include:
- Whether NDA 214373 has listed patents.
- Whether any listed patent covers the active ingredient, tablet formulation, method of use, or other approved feature.
- Whether the sponsor has submitted patent information after approval.
- Whether any patent has pediatric exclusivity.
- Whether a generic applicant can file a Paragraph IV certification.
- Whether a use code restricts the scope of a method-of-use patent.
A Paragraph IV challenger would need to establish that each relevant patent is invalid, unenforceable, or not infringed. A lawsuit filed within 45 days of a qualifying Paragraph IV notice can trigger a statutory stay of FDA approval for up to 30 months, subject to litigation developments under the Hatch-Waxman framework.
What generic entry risks exist for Brenzavvy?
Brenzavvy faces meaningful long-term generic risk because its dosage form is a conventional immediate-release tablet and the active ingredient is a small molecule.
Technical generic-entry pathway
A generic sponsor would typically target:
- Same active ingredient.
- Same strength, 20 mg.
- Same route of administration.
- Pharmaceutical equivalence.
- Bioequivalence.
- Comparable dissolution across relevant pH conditions.
- Stability under ICH conditions.
- A substantially similar excipient system or a justified alternative.
The simple dosage form reduces formulation risk. The principal development challenge is likely API access and characterization rather than excipient innovation.
Commercial generic scenarios
| Scenario |
Likely effect |
| One approved generic |
Initial price pressure, limited substitution |
| Several tablet generics |
Rapid reimbursement compression |
| Authorized generic |
Earlier price competition and channel control |
| Fixed-dose combination launch |
Slower erosion in combination-treated patients |
| Strong payer preference for established SGLT2 brands |
Delayed uptake despite approval |
| Supply disruption or API constraint |
Temporary protection for branded supply |
Brenzavvy competes with established SGLT2 inhibitors, including Jardiance, Farxiga, and Invokana. Those products have greater prescriber familiarity and broader cardiovascular, renal, or heart-failure positioning in some indications. Brenzavvy therefore has a stronger commercial argument where price, formulary access, dosing simplicity, or supply reliability outweighs the incumbents’ clinical and commercial entrenchment.
What formulation opportunities exist for Brenzavvy?
Fixed-dose combinations
The strongest formulation opportunity is a fixed-dose combination with another oral antihyperglycemic agent, particularly metformin. Combination products can reduce pill burden and improve formulary positioning.
Other possible combinations include:
- DPP-4 inhibitors.
- Sulfonylureas.
- Thiazolidinediones.
- Oral GLP-1 pathway agents where formulation and regulatory requirements permit.
- Antihypertensive or cardiometabolic combinations in carefully selected populations.
A fixed-dose combination would require new clinical, pharmaceutical equivalence, stability, and dose-selection work. Its commercial value would depend on reimbursement and prescribing patterns rather than excipient differentiation alone.
Modified patient populations
The current tablet platform could support:
- Smaller tablets for patients with dysphagia.
- Orally disintegrating tablets.
- Sprinkle or dispersible presentations.
- Lower-strength tablets for dose flexibility.
- Blister packaging for adherence.
- Unit-dose packaging for institutional use.
Each option creates formulation and regulatory work. The commercial case is strongest when the new presentation addresses a recognized adherence or administration problem.
Excipient substitution
A sponsor could develop an alternative to sodium lauryl sulfate if it seeks a different wetting profile, lower surfactant exposure, or improved tolerability perception. Possible approaches include polysorbate-based systems, sodium stearyl fumarate, or optimized particle engineering. Such changes would require comparative dissolution and bioequivalence assessment.
A lactose-free strategy is already commercially attractive because the identified inactive-ingredient profile does not include lactose. Marketing should focus on verified formulation facts rather than broad excipient-free claims.
What manufacturing and IP barriers remain?
The principal barriers are likely to be API-related:
- Access to qualified bexagliflozin API.
- Control of polymorphic form.
- Control of chiral purity and process impurities.
- Reproducible particle-size distribution.
- Demonstration of impurity stability over shelf life.
- Freedom to operate around process and crystalline-form patents.
- Reliable commercial-scale supply.
A generic manufacturer could reduce risk through early API characterization, a dual-source strategy, and parallel development of at least two excipient systems. The final formulation should be selected on dissolution robustness and scale-up performance rather than lowest laboratory cost.
What licensing opportunities exist for Brenzavvy?
The most commercially relevant licensing structures would involve:
- API licensing: access to qualified bexagliflozin manufacturing technology or an approved API source.
- Authorized generic arrangements: supply or distribution rights with the NDA holder.
- Combination-product licensing: rights to combine bexagliflozin with metformin or another diabetes therapy.
- Regional commercialization: rights outside the United States where SGLT2 competition and reimbursement differ.
- Manufacturing partnerships: contract development and manufacturing support for tablet production and packaging.
Public FDA approval materials establish the regulatory product but do not establish a disclosed excipient-specific licensing agreement. The licensing value is more likely to center on active-ingredient rights, geographic commercialization, or approved-product access.
How does Brenzavvy compare with competing SGLT2 drugs?
| Product |
Active ingredient |
Dosage form |
Core commercial advantage |
| Brenzavvy |
Bexagliflozin |
Oral tablet |
Newer entrant with once-daily dosing |
| Jardiance |
Empagliflozin |
Oral tablet |
Strong cardiovascular and heart-failure positioning |
| Farxiga |
Dapagliflozin |
Oral tablet |
Broad diabetes, heart-failure, and renal use |
| Invokana |
Canagliflozin |
Oral tablet |
Established SGLT2 franchise and clinical history |
Brenzavvy’s excipient system does not create a clear differentiation advantage over these products. Its commercial opportunity depends on clinical adoption, payer access, price, distribution, and possible combination products.
Key Takeaways
- Brenzavvy uses a conventional immediate-release tablet excipient system.
- The listed excipients are microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate.
- Excipient costs should be modest relative to bexagliflozin API and quality-control costs.
- The formulation is readily compatible with conventional generic manufacturing.
- The principal IP risks are likely to involve active-ingredient, crystalline-form, process, and method-of-use patents rather than commodity excipients.
- Standard NCE exclusivity would place the five-year regulatory protection endpoint around December 22, 2028, subject to confirmation of the FDA exclusivity record and patent status.
- Fixed-dose combinations, patient-friendly dosage forms, packaging, and regional licensing are the strongest commercial opportunities.
- Brenzavvy is a small molecule, so future competition will involve ANDAs and Paragraph IV litigation, not biosimilar applications.
FAQs
Is Brenzavvy lactose-free?
The FDA-listed inactive ingredients do not include lactose. The formulation contains microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate (FDA, 2023a).
Can Brenzavvy be made as a generic tablet?
Yes. Its conventional oral tablet format is suitable for an ANDA, subject to patent, exclusivity, API, pharmaceutical-equivalence, and bioequivalence requirements.
Does Brenzavvy have biosimilar competition?
No. Bexagliflozin is a small molecule. Competition would proceed through generic drug applications rather than biosimilar applications.
What is the best Brenzavvy reformulation opportunity?
A fixed-dose combination, especially with metformin, is the most commercially credible reformulation opportunity. Orally disintegrating, dispersible, or lower-strength presentations may address adherence and administration needs.
Which Brenzavvy excipient is most important for dissolution?
Sodium lauryl sulfate is the most directly relevant to wetting and dissolution. Its concentration, distribution, and interaction with bexagliflozin particle properties should receive specific development attention.
References
-
Food and Drug Administration. (2023a). Brenzavvy (bexagliflozin) tablets: Prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2023b). Brenzavvy approval letter and regulatory review materials, NDA 214373. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH.
-
United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.
